A multicenter, randomized, open label, parallel controlled trial for evaluating the efficacy and safety prostaglandin and beraprost sodium in the treatment of patients with type 2 diabetes and abnormal ABI but no typical intermittent claudication symptoms

INTERVENTION: Group 1:Prostaglandin therapy;Group 2:Basic treatment; CONDITION: Lower extremity artery disease PRIMARY OUTCOME: Six minutes walking test;Questionnaires;Neuropathy evaluation;Urinary protein;Any event related to podiatry; INCLUSION CRITERIA: 1. Type 2 diabetes patients, gender is not limited. The diagnostic criteria for type 2 diabetes are in accordance with the 2010 edition of the Guidelines for the Prevention and Treatment of Type 2 Diabetes in China. Greater than or equal to 60 years old and less than 80 years old. Less than 60 years old but greater than 50 years old (including) combined with any risk factors for PAD, such as smoking, hypertension, abnormal lipid metabolism, or diabetes for more than 10 years (inclusive); 2. ABI measurement is less than 0.9 or greater than 1.3 (TBI less than 0.7); 3. Glycated hemoglobin is less than 8%; blood pressure is less than 150/90mmHg; 4. There is no typical intermittent claudication PAD symptoms (with identification points); 5. Clinical diagnosis of DPN (symptoms and signs positive) or TSS abnormalities or abnormal DPN‐CHECK examination; 6. Ambulatory and consistent with long‐term follow‐up conditions; 7. ability to have a normal r